Potential strategies might include using small molecule inhibitors to block the binding of OCT4 to HERVs or using epigenetic drugs to silence EVE activity, thereby reducing OCT4 expression and weakening the CSC population in the tumor (Hosseiniporgham and Sechi, 2023; Dai et al., 2024). The gene discussed is POU5F1; the disease is neoplasm.